Acular LS®
Ketorolac 0.4% · ophthalmic solution
NSAID
Approved uses
Ocular pain and burning or stinging after corneal refractive surgery
One drop QID in the operated eye as needed, for up to 4 days postoperatively.
Post-PRK pain control equals bromfenac 0.09% BID, with no difference in epithelial healing.
OFF-LABELNot in the FDA label for this product
Cystoid macular edema prophylaxis with cataract surgery
One drop QID for 3 days preoperatively, 4 doses within the hour before surgery, then QID for about 4 weeks postoperatively, added to prednisolone acetate 1% QID.
RCT · n=546 · low-risk eyes
Prospective randomized investigator-masked multicenter trial in 546 patients with no recognized CME risk factors. Clinically apparent CME in 0 of 268 on the NSAID plus steroid versus 5 of 278 on steroid alone (p = 0.032); definite or probable CME on OCT in 0 versus 6 (2.4%, p = 0.018); mean retinal thickening 3.9 versus 9.6 microns (p = 0.003), with more than 10 microns of thickening in 26% versus 51% (p < 0.001). Good-quality single trial in low-risk eyes; the broader class evidence is graded low certainty by Cochrane.
Preoperative dosing to reduce LASIK pain
One drop QID starting 48 hours before surgery, one drop just before the keratome pass, and one drop at the conclusion of surgery.
RCT · n=30 · single surgeon
Prospective randomized double-masked contralateral-eye trial in 60 eyes of 30 patients, fellow eye on artificial tears: mean postoperative pain 0.53 versus 1.23 on a 0 to 6 scale (p = 0.002); the intraoperative difference did not reach significance (p = 0.085). No flap slips or microstriae. Off-label on timing, since the labeled regimen is postoperative only; small single-surgeon study.
Contraindications
Previously demonstrated hypersensitivity to any of the ingredients in the formulation
0.4% (4 mg/mL) solution, 5 mL fill in a 10 mL dropper bottle
Nonsteroidal anti-inflammatory drug of the pyrrolo-pyrrole group that, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. Its mechanism of action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Warnings & Precautions
- Delayed healing: Topical NSAIDs may slow or delay healing, topical corticosteroids are also known to slow or delay healing, and concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
- Cross-sensitivity: Potential cross-reactivity with acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. Bronchospasm and exacerbation of asthma have been reported in patients with aspirin or NSAID hypersensitivity or a past history of asthma. Use caution in individuals who have previously exhibited sensitivities to these drugs.
- Increased bleeding time: With some NSAIDs, there is a potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues, including hyphemas, in conjunction with ocular surgery. Use caution with known bleeding tendencies or concomitant drugs that may prolong bleeding time.
- Corneal effects: Keratitis can occur, and continued use in susceptible patients may progress to epithelial breakdown, corneal thinning, erosion, ulceration, or perforation, which may be sight threatening. Discontinue immediately on corneal epithelial breakdown and monitor corneal health closely.
- Corneal adverse events: Postmarketing experience suggests patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases such as dry eye, rheumatoid arthritis, or repeat ocular surgeries within a short period may be at increased risk for corneal adverse events, which may become sight threatening; use with caution in these patients. Use more than 1 day before or beyond 14 days after surgery may increase their occurrence and severity.
- Contact lens wear: Not to be administered while wearing contact lenses.
- Risk of contamination: Do not allow the bottle tip to contact the eye or surrounding structures, because the tip could become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Common Side Effects
Conjunctival hyperemia, corneal infiltrates, headache, ocular edema, and ocular pain were the most frequent adverse reactions with Acular LS, in approximately 1 to 5% of patients. Transient stinging and burning on instillation have been the most frequent reactions with ketorolac tromethamine ophthalmic solutions, reported by up to 40% of trial patients, and corneal ulcer, eye dryness, and blurry vision were reported rarely. With other ketorolac tromethamine ophthalmic solutions, allergic reactions (including eye swelling, eyelid edema, and hyperemia), corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis, and superficial ocular infections occurred approximately 1 to 10% of the time. Postmarketing reports include bronchospasm or exacerbation of asthma, corneal erosion, corneal perforation, corneal thinning and corneal melt, and epithelial breakdown.
Pregnancy: No adequate or well-controlled studies in pregnant women; no teratogenicity seen in rats or rabbits at clinically relevant doses.
Lactation: Presence in human milk after topical dosing is unknown; use caution in a nursing woman.
Safety and effectiveness not established below age 3.